ArticleHaematologica2018
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.Frontiers in oncology · 2025Pooled it
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.Haematologica · 2022Trial
- Trial
- The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study.BMC cancer · 2025Article
- Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury.Blood advances · 2025Article
- Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study.Therapeutic advances in medical oncology · 2025Article
- Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis.Therapeutic advances in hematology · 2025Article
- The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.CEN case reports · 2022Article
- High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury.Frontiers in oncology · 2022Review
- Speckle Noise Algorithm-Based Ultrasound Imaging in Evaluating the Therapeutic Effect of Blood Purification on Children with Kidney Failure and Analysis of Its Correlation with Serum Inflammatory Factor Levels.Journal of healthcare engineering · 2022Article
- An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.Therapeutic advances in hematology · 2022Review
- Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists.Frontiers in oncology · 2021Article
- Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis.Therapeutic advances in hematology · 2021Review
- Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimen.International journal of hematology · 2020Article
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.Journal for immunotherapy of cancer · 2020Article
- Daratumumab in dialysis-dependent multiple myeloma.Blood research · 2020Article
- Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure.Irish journal of medical science · 2019Article
- Recent Updates in the Diagnosis and Management of Kidney Diseases in Multiple Myeloma.Indian journal of nephrologyReview
- Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.Journal of clinical and experimental hematopathology : JCEHArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.